Best Practices in Switching PBC Therapies

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL ,Sandy Sallam, PharmD, BCACP, CDCES

Panelists discuss how clinicians may transition patients to newer agents due to factors such as inadequate biochemical response, tolerability issues (particularly pruritus), or patient preference, while carefully considering the need for washout periods based on each drug's pharmacokinetics and mechanism of action.

EP: 1.Presentation and Diagnosis of Primary Biliary Cholangitis

EP: 2.Available Treatment Options for PBC

EP: 3.Treatment Goals for Patients With PBC

EP: 4.Exploring Second-Line Treatments for PBC

EP: 5.Examining Elafibranor as a Treatment Option for PBC

EP: 6.Discussing Seladelpar as a Potential Therapeutic for PBC

EP: 7.Long-Term Considerations for PBC Treatment Options

EP: 8.Safety Considerations When Initiating Treatment for PBC

EP: 9.Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies

EP: 10.Additional Safety Considerations With PBC Treatments

EP: 11.Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis

EP: 12.Long-Term Safety of Second-Line Therapies for PBC

Now Viewing

EP: 13.Best Practices in Switching PBC Therapies

EP: 14.Monitoring Patients Transitioning From Obeticholic Acid

Video content above is prompted by the following:

What are some reasons why clinicians may consider a transition from obeticholic acid to seladelpar or elafibranor for PBC?
Given the different mechanisms of action of obeticholic acid, seladelpar, and elafibranor, what factors should be considered in determining the need for a washout period between treatments vs direct transition?